F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1619-7089
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients ; day:26 ; month:11 ; year:2016 ; pages:1-11
European journal of nuclear medicine and molecular imaging ; (26.11.2016), 1-11
- Schlagwort
-
Krebs
Onkologie
- Urheber
- Beteiligte Personen und Organisationen
-
Hadaschik, Boris
Cardinale, J.
Radtke, J.
Vinsensia, M.
Lehnert, W.
Kesch, Claudia
Tolstov, Y.
Singer, S.
Grabe, Niels
Duensing, Stefan
Schäfer, M.
Kiß, Oliver
Mier, W.
Haberkorn, Uwe
Kopka, K.
Kratochwil, Clemens
SpringerLink (Online service)
- DOI
-
10.1007/s00259-016-3573-4
- URN
-
urn:nbn:de:1111-201701127839
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:59 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Giesel, Frederik L.
- Hadaschik, Boris
- Cardinale, J.
- Radtke, J.
- Vinsensia, M.
- Lehnert, W.
- Kesch, Claudia
- Tolstov, Y.
- Singer, S.
- Grabe, Niels
- Duensing, Stefan
- Schäfer, M.
- Kiß, Oliver
- Mier, W.
- Haberkorn, Uwe
- Kopka, K.
- Kratochwil, Clemens
- SpringerLink (Online service)
Ähnliche Objekte (12)
Preclinical biodistribution and dosimetry and human biodistribution comparing 18F-rhPSMA-7 and single isomer 18F-rhPSMA-7.3
EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor- and PSMA-targeting ligands
18F-Labelled PSMA-1007 shows similarity in structure, biodistribution and tumour uptake to the theragnostic compound PSMA-617
Development and dosimetry of 203Pb/212Pb-labelled PSMA ligands: bringing “the lead” into PSMA-targeted alpha therapy?
99mTc-labelled S-HYNIC certolizumab pegol in rheumatoid arthritis and spondyloarthritis patients: a biodistribution and dosimetry study
Biodistribution and dosimetry for combined [177Lu]Lu-PSMA-I&T/[225Ac]Ac-PSMA-I&T therapy using multi-isotope quantitative SPECT imaging
Physiological biodistribution on Ga68-PSMA PET/CT and the factors effecting biodistribution
Preclinical comparison of [177Lu]Lu-rhPSMA-10.1 and [177Lu]Lu-rhPSMA-10.2 for endoradiotherapy of prostate cancer: biodistribution and dosimetry studies
Biodistribution and dosimetry of a single dose of albumin-binding ligand [177Lu]Lu-PSMA-ALB-56 in patients with mCRPC
Human biodistribution and radiation dosimetry of the demyelination tracer [18F]3F4AP
Influence of sampling schedules on [177Lu]Lu-PSMA dosimetry
Human Biodistribution and Radiation Dosimetry of the P-Glycoprotein Radiotracer [11C]Metoclopramide
Preclinical biodistribution and dosimetry and human biodistribution comparing 18F-rhPSMA-7 and single isomer 18F-rhPSMA-7.3
EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor- and PSMA-targeting ligands
18F-Labelled PSMA-1007 shows similarity in structure, biodistribution and tumour uptake to the theragnostic compound PSMA-617
Development and dosimetry of 203Pb/212Pb-labelled PSMA ligands: bringing “the lead” into PSMA-targeted alpha therapy?
99mTc-labelled S-HYNIC certolizumab pegol in rheumatoid arthritis and spondyloarthritis patients: a biodistribution and dosimetry study
Biodistribution and dosimetry for combined [177Lu]Lu-PSMA-I&T/[225Ac]Ac-PSMA-I&T therapy using multi-isotope quantitative SPECT imaging
Physiological biodistribution on Ga68-PSMA PET/CT and the factors effecting biodistribution
Preclinical comparison of [177Lu]Lu-rhPSMA-10.1 and [177Lu]Lu-rhPSMA-10.2 for endoradiotherapy of prostate cancer: biodistribution and dosimetry studies
Biodistribution and dosimetry of a single dose of albumin-binding ligand [177Lu]Lu-PSMA-ALB-56 in patients with mCRPC
Human biodistribution and radiation dosimetry of the demyelination tracer [18F]3F4AP
Influence of sampling schedules on [177Lu]Lu-PSMA dosimetry
Human Biodistribution and Radiation Dosimetry of the P-Glycoprotein Radiotracer [11C]Metoclopramide
Preclinical biodistribution and dosimetry and human biodistribution comparing 18F-rhPSMA-7 and single isomer 18F-rhPSMA-7.3
EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor- and PSMA-targeting ligands
18F-Labelled PSMA-1007 shows similarity in structure, biodistribution and tumour uptake to the theragnostic compound PSMA-617
Development and dosimetry of 203Pb/212Pb-labelled PSMA ligands: bringing “the lead” into PSMA-targeted alpha therapy?
99mTc-labelled S-HYNIC certolizumab pegol in rheumatoid arthritis and spondyloarthritis patients: a biodistribution and dosimetry study
Biodistribution and dosimetry for combined [177Lu]Lu-PSMA-I&T/[225Ac]Ac-PSMA-I&T therapy using multi-isotope quantitative SPECT imaging
Physiological biodistribution on Ga68-PSMA PET/CT and the factors effecting biodistribution
Preclinical comparison of [177Lu]Lu-rhPSMA-10.1 and [177Lu]Lu-rhPSMA-10.2 for endoradiotherapy of prostate cancer: biodistribution and dosimetry studies
Biodistribution and dosimetry of a single dose of albumin-binding ligand [177Lu]Lu-PSMA-ALB-56 in patients with mCRPC
Human biodistribution and radiation dosimetry of the demyelination tracer [18F]3F4AP
Influence of sampling schedules on [177Lu]Lu-PSMA dosimetry